

CURRICULUM VITAE

Prof. Luciano Mutti MD

prof.lucianomutti@gmail.com

EDUCATION AND QUALIFICATIONS

- 1982** M .D. training completed with Magna cum laude, Genoa University
- 1983** Post degree training in General Medicine meeting the standards laid down in Article 23 of the European Medical Directive 93/16/EEC (GTP equivalent) and MRCP
- 1988** CCT equivalent in Respiratory Medicine, Genoa University
- 1991** CCT equivalent in Respiratory Pathophysiology, Genoa University
- 1994** Ph.D in Oncology programme completed, Turin University
- 2012** RCPI Appraised Specialist Register for Medical Oncology, Dublin, Ireland
- 2021** Granted with the Italian National Scientific License for Full Professorship in Oncology (ASN MEDS/09)

ACADEMIC ACTIVITIES AND APPOINTMENTS

- 1998** Visiting Professor Brown University , Providence R.I. (U.S.)
- 1999** Visiting Professor Loyola University of Chicago (U.S.)

- 2009** Visiting Professor, University of Hawaii
to 2012
- 2014** Chair in Cancer Research, Full Professor
to Salford University, Manchester UK
2018
- 2018** Adj Professor in Translational Cancer Research Sbarro Institute for Cancer
to date Research and Molecular Medicine, Center for Biotechnology, College of
of Science and Technology, Temple University, Philadelphia, USA
- 2022** Professor of Oncology University of L'Aquila MEDS/09
to 2025
- 2024** Professor of Oncology at University of Buckingham (UK)
to date

ADMINISTRATIVE APPOINTMENTS

- from** Associate Director Department of Medicine
1993 Local Health 11 Vercelli, Italian NHS
to Fully responsible for clinical and research activity
1996
- from** Associate Director
1996 Occupational Diseases Institute for Research and Care Pavia
to In conjunction with Dept of Oncology Turin University
1999 Practice of General and Respiratory medicine with particular interest in
Thoracic oncology
- from** Head of Department - General Medicine/Director Unit of Translational
1999 Research for Thoracic Medical Oncology
to Scientific Director of the Laboratory of Clinical Oncology
2014 Vercelli Teaching Hosp
- from** Free Lance Counselling Director of the Oncology Unit for TTH Ltd
2018 As Director of Oncology at TTH I have established,
to started up and developed a new Unit of Comprehensive Medical
2020 Oncology
- from** Head of Dept of Medical Oncology S. Salvatore Hospital, L'Aquila

2022
to
2025

from
2021
to
2025

Director of the ASL1 Abruzzo Oncology Network

CLINICAL/HOSPITAL APPOINTMENTS

from 2022 to 2025 Head of Oncology Dept. S.Salvatore Hospital, L'Aquila

from 2018 to 2019 Head of Oncology Dept. and Consulant TTH Hospital

from 2014 to 2018 Consultant of Thoracic Medical Oncology and General Medicine at Manchester University Hosp.

from 1999 to 2014 Head of Dept General Medecine and Consultant Thoracic Medical Oncology Vercelli Teaching Hospital

2014 Consultant Medical Oncology North Middlesex University Hosp
London UK

2012- 2013 Consultant Medical Oncology, Oxford University Hosp., UK

2010-2011 Consultant - Medical Oncology, Coventry University Hospital, UK

2009-2010 Consultant - Medical Oncology, Bon Secours Hospital, Cork, IE

2008 Consultant - Medical Oncology, St. James Hospital, Dublin, IE

HONORS AND AWARDS

- 2008** Winner of the Italian National Award for the the Research on Asbestos Related Tumours granted by the Italian National Association for Labour
- 2014** Winner of the prize "Scientist of the Year" granted by Piedmont College of Journalists
- 2019** "Fair Play" Award for Scientific Research. Olympic National Committee Selected amid the best 100 Thoracic Italian Oncologists (ALCASE)
- 2022** Winner AACR Prize, ACCR Kyoto, Japan
- 2025**

MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES

- AIOM member
- FM/TF member European Respiratory Society
- FM International Society of Translational Medicine
- Expert Leader of European Respiratory Society for "Chemotherapy and Novel Therapies for Pleural Mesothelioma
- Member of the European TF for the standardization of the procedures in Thoracic Oncology
- Registered in Reprise (The Register of Scientific Expert of MUR)
- Member of Scientific Committee for Independent Research Entitled Therapeutic NGS in Oncology
- FM ACCR

past

- Member of the Piedmont Oncology Board for the study of MM.
- Consultant for the Italian Foreign Affairs Ministry for the U.S.A-Italy. scientific cooperation
- Consultant of the National Toxicology Commission
- Member of the Committee of the Advanced Biotechnology Center (CBA), Genoa
- Chairman of the Scientific Committee Fondazione Buzzi for Pleural Mesothelioma
- Member of the Science Advisory Board Mesothelioma Applied Research Foundation
- Member of the IASLC TF for new therapeutic targets for malignant pleural mesothelioma
- Italian Director of the International Mesothelioma Interest Group (IMIG www.imig.org)

EXTRAMURAL INVITED SPEAKER/CHAIRMAN (last 10 years)

2014. 20-23 Feb. Third meeting on translational research for cancer, Honolulu, US
10-13 March, Mesothelioma Applied Research Foundation Annual Meeting, Washington, US
20-21 March; International Meeting on Legal and Health implications of exposure to asbestos, Rome.

22-25 October Chairman and Invited Speaker XXI IMIG Meeting, Cape Town

2015. 17-19 July, Invited Speaker UK/China against cancer (Cardiff) UK.

24-25 October. Current State of the Art on asbestos-related tumors. Trieste. Italy

20 Nov . Keynote Lecture at EU parliament on the effect of asbestos exposure on human health. Brussel

11-12 November 2015. Key note at the conference Novel treatments for Cancer. Cairo, Egypt

2016. March. New perspective to tackle asbestos-related tumour. House of Commons. London, UK

May LOC and Chair r and LOC IMIG International Meeting Birmingham, UK

June. Translational Therapies: a new scenario for human diseases, Manchester, UK Dec:

Invited Speaker, IASLC Annual meeting, Vienna

2017. March. MARF meeting, Washington. Chair and Invited Speaker

October 2017, Cancer Care Conference 2017: Delivering World Class Care, Salford, UK

2018. May Chair IMIG Congress, Ottawa (Canada)

2019. Sept:Lisbon: Annual Meeting European Society of Thoracic Surgery, speaker

Barcelona IASLC Congress, chair

2021. On line Cancer bio-immunotherapy in the Covid era.

Co-chairman

2022.29-30 June, 1st of July. International Meeting " Novel Approaches for Cancer Treatment"

Chairman and Invited Speaker

29 Sep/1 October. National Meeting of Thoracic Endoscopy, Chair

2023. 27-28 January. Medical Oncology Today, Bari Italy , Invited Speaker

17-18 February. Precision Oncology for NSCLC, Giulianova, Italy. Chair

1 April 17th Conference Italian Researchers in the World, Philadelphia, invited Speaker

21-22 April. Chest Wall tumor National Meeting , Giulianova, I Invited Speaker

3 May . First Meeting of Precision Oncology. Pescara, I. Panelist

9-10 June Taking care of cancer patients from therapies to communication. L' Aquila, I Chair

21 June. First Italian Meeting of Onco-rheumatology, Rome, I. Board Member
26-28 June 16th IMIG Meeting, Lille, Fr. Organizing committee and Invited Key Speaker
5-6 May. Global approach to HCC. L' Aquila, I Invited Speaker
10 July. First Regional Cancer Molecular Board. Teramo, I. Panelist
5 Sep Molecular Tumor Board for Lung Cancer L' Aquila, I. Chair and Chairman
15 Sept. International Meeting. Cutting edge advancement against cancer. L' Aquila, I
Chairman and Scientific Director

2024. 11 April. Immunotherapy for Melanoma, Chair, Lanciano, I
12-13 April. Onco-rheumatology, invited speaker, Paestum, I
19. April. Pharma-day 2024, chair and invited speaker, L' Aquila, I
20. April. Regional meeting respiratory diseases, Chair, L' Aquila, I
10 July. Workshop Onco-rheumatology, board member, Olbia,
I 9 Sept. Vaccines for cancer patients, invited speaker,
Pescara, I
20-21 Sept. Management of GI diseases. Invited Speaker, L' Aquila, I
9-12 October. National Meeting Rheumatology College, Chair, Firenze, I
24-25 October. Second Meeting Cutting edge advancement against cancer. L' Aquila,
Chairman and Scientific Director
26 October. From Diagnoses to therapy for Breast and Lung Cancer and Melanoma,
invited speaker, Lanciano, I
23 Nov. A year in Oncology, Key-Note lecture, Chieti, I

2025 26-29 March ELCC, poster presentation "Adenosine pathways", Paris
25-30 April AACR Meeting, Poster presentation Adenosine in cancer, Chicago
28-30 June JCA-AACR Precision Cancer Medicine Poster presentation, Kyoto Japan
22-26 October AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Therapeutics Poster Presentation Boston (USA)

Journal Editorial Activities and Review Committee Memberships

Member of the Editorial Board of the Journal, Frontiers Oncology, E- Biomedicine
Biomedicine, ISRN Oncology, Academic Editor of Academia Medicine
Peer reviewer, among others, for Cancer Research, Clin Cancer Res, European
Respiratory Journal, PNAS, JTO.

TEACHING

In Italy prior to moving to the UK my main teaching activity has been of as Honorary Senior Lecturer for UG (MD and PhD) and PG (Masters) students As Chair in Cancer Research at Salford University in Manchester I gave lectures (Modules of Cellular Basis of Diseases, Applied Biomedical Sciences, Drug Design, Clinical immunology) and led tutorial and supervise Final Year Research Projects, Masters students and PhD

At Manchester Royal University Hospital (MRI) I was responsible of teaching activity in General Medicine and Oncology to UG and PG medical students Am currently teaching Medical Oncology and Cancer biology to UG and PG students at L'Aquila University in Italy and Oncology to PG students at Buckingham University in the UK

As Adj Professor at Temple University am responsible of teaching translational cancer research for UG and PG student

As Professor at University of L'Aquila I was responsible of Teaching Medical Oncology UG and PG students

At Buckingham University I am responsible of Teaching in Oncology Master Programs

RESEARCH

Personal Statement

I have spent a very significant portion of my career to achieve a better understanding of Mesothelioma (MM) biology and specific druggable targets for this tumor.

My most relevant ability is bridging the gap between the preclinical and clinical activities. This approach covers several human tumors even though we have been addressing our efforts mainly toward thoracic malignancies and particularly MM.

I have a long and successful experience as a leader of a big translational group of pre-clinical and clinical scientist working on this tumor and I have been contributing to European Guidelines for MM from 2010 to date. As a Director of the Scientific Committee of Buzzi Foundation for study and Therapy of MM and Head of Dept in Vercelli Teaching University Hosp, I lead a multidisciplinary group including Molecular Biology, Epidemiology and Molecular Epidemiology and Clinical Sciences. I have successfully conducted

many studies requiring the coordination of a complex international team including Hospital and Academic Institutions.

More in general terms I have studied the immune response to MM as it follows: I have published the first paper suggesting that MM cells have the potential to elicit a T-cell mediated immune response, however the same

tumor cells induce immune-suppression via TGFB and AKT activation although do express Cancer Testis Antigens (CTA). I have also provided with the rationale of using anti-CTLA4 for MM and tested their efficacy for MM in the first trial with ICIs ever conducted worldwide.

1. Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. PMID: 9833768 Cited by 41
2. Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone. PMID: 12525871. Cited by 15
3. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral- related carcinogenesis of human malignant mesothelioma. PMID: 11572935; PMCID: PMC59762. Cited by 180
4. Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications..Cited by 26
5. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open- label, single-arm, phase 2 trial PMID: 24035405. Cited by 428

All of my translational research activity is aimed at leading as a PI and managing multidisciplinary groups to translate of our pre-clinical findings into clinical practice and clinical trials. The current front line therapy for MM including antiangiogenic is the direct outcome of our preclinical and translational studies. I pioneered research on Mesothelioma back in early 90s, and started, together with Marie Claude Jaurand, Bruce Robinson and a few others, the IMIG in Paris in 1993. I have dedicated the career to the care of patients with mesothelioma to develop new treatments based on solid preclinical research.

Contributions to Science

All of my translational research activity is aimed at leading as a PI and managing multidisciplinary groups to translate of our pre-clinical findings into clinical practice and clinical trials. The current front-line therapy for Mesothelioma including antiangiogenic is the direct outcome of our preclinical and translational studies. I pioneered research on Mesothelioma back in early 90s, and started, together with Marie Claude Jaurand, Bruce Robinson and a few others, the IMIG in Paris in 1993. I have dedicated the career to the care of patients with mesothelioma to develop new treatments based on solid preclinical research.

Here below the link to my publications on Mesothelioma so far as per those listed on pubmed.gov:

<https://pubmed.ncbi.nlm.nih.gov/?term=Mutti+L.+mesothelioma&sort=pubdate>

Here below what our most significant contribution to science and Mesothelioma (Google Scholar)

Use of Antiangiogenic for MPM

The first three papers provided with the first evidences that paved the way to the use of anti-angiogenic therapies for mesothelioma now included into clinical guidelines

- 1.** Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. PMID: 11276005. Cited by 476.
- 2.** The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. PMID: 11804869. Cited by 82
- 3.** Will antiangiogenic agents be a future for mesothelioma therapy? PMID: 20629625. Cited by 5
- 4.** RAMES study: is there really a role for VEGF inhibition in mesothelioma? LO PMID: 34856142. Cited by 5

Role of actionable TKI and PI3K/AKT signaling in MM

These papers uncovered the role of TKR in mesothelioma and suggested that these were actionable targets. Many followed these ideas that were initially developed by our group.

- 1.** SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res PMID: 15958571. Cited by 107
- 2.** Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax. 2007 Aug;62(8):690-5. doi: 10.1136/thx.2006.069872. Epub 2007 Feb 20. PMID: 17311837; PMCID: PMC2117287. Cited by 62
- 3.** Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. PMID: 18223230. Cited by 79
- 4.** Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. Genes Cancer. PMID: 28435517; PMCID: PMC5396622. Cited by 21

Immune Check Inhibitor (ICI) and PARPi as novel therapeutic tools against MM

The first clinical trial ever published on the use of ICi, and based on the preclinical research quoted in the "Personal Statement". As far as PARPi six years later our trailblazer paper was the first trial with Olaparib for MM started. The interested reader will find the rationale of these clinical trials in our papers below.

- 1.** Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma.. 2024 Apr;19(4):541-546. doi: 10.1016/j.jtho.2024.01.016. PMID: 38582546. Cited by 5
- 2.** Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. PMID: 32206576 Cited by 55
- 3.** Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial PMID: 24035405. Cited by 428
- 4.** Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer. 2002 Mar 18;86(6):979-82. doi: 10.1038/sj.bjc.6600174. PMID: 11953832; PMCID: PMC2364149. Cited by 28
- 5.** Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma. PMID: 35262715; PMCID: PMC8908075. Cited by 45
- 6.** PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. PMCID: PMC3822586. Cited by: 40

Guidelines for MM and Lung Cancer

In 2010 and 2020, I have participated in the only two world-wide Cochrane- analyses based guidelines for Mesothelioma, and established the criteria for Lung Cancer Center for Diagnosis and Therapy.

- 1.** ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2020 Jul 1;58(1):1-24. doi: 10.1093/ejcts/ezaa158. PMID: 32448904. Cited by 69
- 2.** ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020 Jun 11;55(6):1900953. PMID: 32451346. Cited by 241
- 3.** ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe. Eur Respir J. 2018 Dec 20;52(6):1800610. doi: 10.1183/13993003.00610-2018. PMID: 30361252. Cited by 10
- 4.** Surgery for malignant pleural mesothelioma: an international guidelines review. J Thorac Dis. 2018 PMID: 29507797; PMCID: PMC5830571 Cited by 54

5. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le Pécoux C, Mutti L, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W; European Respiratory Society/European Society of Thoracic Surgeons Task Force. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. *Eur Respir J.* 2010 Mar;35(3):479-95. doi: 10.1183/09031936.00063109. Epub 2009 Aug 28. PMID: 19717482.

Cited 786

Viral Carcinogenesis and MM

These papers highlight the role of SV40 in MM and human carcinogenesis

- 1.** SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. *Cancer Res.* 2005 PMID: 15833832.Cited by 114
- 2.** Association of SV40 with human tumours. *Semin Cancer Biol.* 2001 Feb;11(1):49-61. PMID: 11243899. Cited by 134
- 3.** Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Cited by 75
- 4.** Simian virus 40-like DNA sequences and large-T antigen-retinoblastoma family protein pRb2/p130 interaction in human mesothelioma. PMID: 9776225.Cited by 18

References:

- 1. Mutti L**, Piacenza A, Guaschino R, Castagneto B, Betta PG. Gamma/delta T-lymphocytes in advanced pulmonary asbestosis. *Sarcoidosis*. 1993 Sep;10(2):169-71. PMID: 8140322.
- 2. Mutti L**, Piacenza A, Valenti V, Castagneto B, Betta PG. Expression of intercellular adhesion molecule-1 (ICAM-1) by reactive mesothelial cells in pleural effusions. *Pathologica*. 1993 Nov-Dec;85(1100):725-8. PMID: 7909596.
- 3. Scagliotti G**, Gatti E, Ferrari G, **Mutti L**, Pozzi E. Tnp-alpha determination in serum and pleural effusion in patients with lung-cancer. *Int J Oncol*. 1995 Jan;6(1):147-51. PMID: 21556515.
- 4. Stacchini A**, Fubini L, Gatti E, **Mutti L**, Piacibello W, Sanavio F, Scagliotti G, Pozzi E, Aglietta M. In vivo effect of human granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil GM-CSF receptors. *Leukemia*. 1995 Apr;9(4):665-70. PMID: 7723402.
- 5. Gatti E**, Scagliotti GV, Ferrari G, **Mutti L**, Pozzi E, Stacchini A, Fubini L, Aglietta M. Blood cell redistribution in the lung after administration of recombinant human granulocyte-macrophage colony-stimulating factor. *Eur Respir J*. 1995 Sep;8(9):1566-71. PMID: 8575586.
- 6. Rizzo P**, Di Resta I, Stach R, **Mutti L**, Picci P, Kast WM, Pass HI, Carbone M. Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas. *Dev Biol Stand*. 1998;94:33-40. PMID: 9776223.
- 7. Orengo AM**, Spoletini L, Procopio A, Favoni RE, De Cupis A, Ardizzoni A, Castagneto B, Ribotta M, Betta PG, Ferrini S, **Mutti L**. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. *Eur Respir J*. 1999 Mar;13(3):527-34. doi: 10.1183/09031936.99.13352799. PMID: 10232421.
- 8. Emri S**, Kocagoz T, Olut A, Güngen Y, **Mutti L**, Baris YI. Simian virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey. *Anticancer Res*. 2000 Mar-Apr;20(2A):891-4. PMID: 10810372.
- 9. Porta C**, Danova M, Orengo AM, Ferrini S, Moroni M, Gaggero A, Libener R, Betta PG, Ferrari S, Procopio A, Strizzi L, **Mutti L**. Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro. *J Cell Physiol*. 2000 Oct;185(1):126-34. doi: 10.1002/1097-4652(200010)185:1<126::AID-JCP12>3.0.CO;2-2. PMID: 10942526.
- 10. Procopio A**, Strizzi L, Vianale G, Betta P, Puntoni R, Fontana V, Tassi G, Gareri F, **Mutti L**. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. *Genes Chromosomes Cancer*. 2000 Oct;29(2):173-9. doi: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1019>3.0.co;2-b. PMID: 10959097.
- 11. Di Muzio M**, Spoletini L, Strizzi L, Vianale G, Fontana V, Orengo MA, Tassi G, Casalini A, **Mutti L**, Procopio A. Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma. *Hum Pathol*.

2000 Nov;31(11):1341-5. doi: 10.1053/hupa.2000.19459. PMID: 11112207.

12. Procopio A, Strizzi L, Vianale G, Betta P, Puntoni R, Fontana V V, Tassi G, Gareri F, **Mutti**

L. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant

pleural mesothelioma. *Genes Chromosomes Cancer*. 2001 Jan;30(1):111. doi: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1064>3.0.co;2-l. PMID: 11107186.

- 13.**Castagneto B, Zai S, **Mutti L**, Lazzaro A, Ridolfi R, Piccolini E, Ardizzoni A, Fumagalli L, Valsuani G, Botta M. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. *Lung Cancer*. 2001 Feb-Mar;31(2-3):303-10. doi: 10.1016/s0169-5002(00)00192-6. PMID: 11165411.
- 14.**Jasani B, Cristaudo A, Emri SA, Gazdar AF, Gibbs A, Krynska B, Miller C, **Mutti L**, Radu C, Tognon M, Procopio A. Association of SV40 with human tumours. *Semin Cancer Biol*. 2001 Feb;11(1):49-61. doi: 10.1006/scbi.2000.0346. PMID: 11243899.
- 15.**Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, **Mutti L**, Procopio A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. *J Pathol*. 2001 Apr;193(4):468-75. doi: 10.1002/path.824. PMID: 11276005.
- 16.**Strizzi L, Vianale G, Catalano A, Muraro R, **Mutti L**, Procopio A. Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. *Int J Oncol*. 2001 May;18(5):1093-8. doi: 10.3892/ijo.18.5.1093. PMID: 11295061.
- 17.**Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A, Strizzi L, Penengo L, Tognon M, **Mutti L**, Gaudino G. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. *Proc Natl Acad Sci U S A*. 2001 Oct 9;98(21):12032-7. doi: 10.1073/pnas.211026798. Epub 2001 Sep 25. PMID: 11572935; PMCID: PMC59762.
- 18.**Cacciotti P, Strizzi L, Vianale G, Iaccheri L, Libener R, Porta C, Tognon M, Gaudino G, **Mutti L**. The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. *Am J Respir Cell Mol Biol*. 2002 Feb;26(2):189-93. doi: 10.1165/ajrcmb.26.2.4673. PMID: 11804869.
- 19.**Sigalotti L, Coral S, Altomonte M, Natali L, Gaudino G, Cacciotti P, Libener R, Colizzi F, Vianale G, Martini F, Tognon M, Jungbluth A, Cebon J, Maraskovsky E, **Mutti L**, Maio M. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. *Br J Cancer*. 2002 Mar 18;86(6):979-82. doi: 10.1038/sj.bjc.6600174. PMID: 11953832; PMCID: PMC2364149.
- 20.**Strizzi L, Muraro R, Vianale G, Natoli C, Talone L, Catalano A, **Mutti L**, Tassi G, Procopio A. Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. *J Pathol*. 2002 Jun;197(2):218-23. doi: 10.1002/path.1125. PMID: 12015746.
- 21.**Toma S, Colucci L, Scarabelli L, Scaramuccia A, Emionite L, Betta PG, **Mutti L**. Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines. *J Cell Physiol*. 2002 Oct;193(1):37-41. doi: 10.1002/jcp.10150. PMID: 12209878.

22.Bolognesi C, Filiberti R, Neri M, Perrone E, Landini E, Canessa PA, Simonassi C, Cerrano PG, **Mutti L**, Puntoni R. High frequency of micronuclei in peripheral blood lymphocytes as index of susceptibility to pleural malignant mesothelioma. *Cancer Res.* 2002 Oct 1;62(19):5418-9. PMID: 12359747.

- 23.**Porta C, Rizzo V, Zimatore M, Sartore-Bianchi A, Danova M, **Mutti L**. Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity? *Lung Cancer*. 2002 Nov;38(2):159-62. doi: 10.1016/s0169-5002(02)00187-3. PMID: 12399127.
- 24.**Cerrano PG, Jasani B, Filiberti R, Neri M, Merlo F, De Flora S, **Mutti L**, Puntoni R. Simian virus 40 and malignant mesothelioma (Review). *Int J Oncol*. 2003 Jan;22(1):187-94. PMID: 12469203.
- 25.**Valle MT, Porta C, Megiovanni AM, Libener R, Mele L, Gaudino G, Strizzi L, Guida R, Toma S, **Mutti L**. Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone. *Int J Mol Med*. 2003 Feb;11(2):161-7. PMID: 12525871.
- 26.**Carbone M, Bocchetta M, Cristaudo A, Emri S, Gazdar A, Jasani B, Lednický J, Miele L, **Mutti L**, Pass HI, Ramael M, Rizzo P, Testa JR, Weggen S, Yeung A. SV40 and human brain tumors. *Int J Cancer*. 2003 Aug 10;106(1):140-2; author reply 143-5. doi: 10.1002/ijc.11189. PMID: 12794770.
- 27.****Mutti L**, Broaddus VC. Malignant mesothelioma as both a challenge and an opportunity. *Oncogene*. 2004 Dec 9;23(57):9155-61. doi: 10.1038/sj.onc.1208180. PMID: 15516978.
- 28.**Cristaudo A, Foddìs R, Vivaldi A, Buselli R, Gattini V, Guglielmi G, Cosentino F, Ottenga F, Ciancia E, Libener R, Filiberti R, Neri M, Betta P, Tognon M, **Mutti L**, Puntoni R. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. *Cancer Res*. 2005 Apr 15;65(8):3049-52. doi: 10.1158/0008-5472.CAN-04-2219. PMID: 15833832.
- 29.**Ramos-Nino ME, Vianale G, Sabo-Attwood T, **Mutti L**, Porta C, Heintz N, Mossman BT. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. *Mol Cancer Ther*. 2005 May;4(5):835-42. doi: 10.1158/1535-7163.MCT-04-0243. PMID: 15897248.
- 30.**Ramos-Nino ME, Vianale G, Sabo-Attwood T, **Mutti L**, Porta C, Heintz N, Mossman BT. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. *Mol Cancer Ther*. 2005 May;4(5):835-42. doi: 10.1158/1535-7163.MCT-04-0243. PMID: 15897248.
- 31.**Porta C, Zimatore M, Bonomi L, Imarisio I, Paglino C, Sartore-Bianchi A, **Mutti L**. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. *Lung Cancer*. 2005 Jun;48(3):429-34. doi: 10.1016/j.lungcan.2004.11.015. Epub 2005 Jan 24. PMID: 15893013.
- 32.**Vogelzang NJ, Porta C, **Mutti L**. New agents in the management of advanced mesothelioma. *Semin Oncol*. 2005 Jun;32(3):336-50. doi: 10.1053/j.seminoncol.2005.02.010. PMID: 15988688.
- 33.**Cacciotti P, Barbone D, Porta C, Altomare DA, Testa JR, **Mutti L**, Gaudino G. SV40- dependent AKT activity drives mesothelial cell transformation after asbestos exposure. *Cancer Res*. 2005 Jun 15;65(12):5256-62. doi:

10.1158/0008-5472.CAN-05-0127. PMID: 15958571.

34.Bolognesi C, Martini F, Tognon M, Filiberti R, Neri M, Perrone E, Landini E, Canessa PA, Ivaldi GP, Betta P, **Mutti L**, Puntoni R. A molecular epidemiology case control study on

pleural malignant mesothelioma. *Cancer Epidemiol Biomarkers Prev.* 2005 Jul;14(7):1741-6. doi: 10.1158/1055-9965.EPI-04-0903. PMID: 16030111.

35.Porta C, Ardizzoni A, Gaudino G, Maio M, **Mutti L**, Pinto C, Porru S, Puntoni R, Tassi G, Tognon M. Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group. *Med Lav.* 2005 Jul-Aug;96(4):360-9.

PMID: 16457433.

36.Porta C, Ardizzoni A, Gaudino G, Maio M, **Mutti L**, Pinto C, Porru S, Puntoni R, Tassi G, Tognon M. Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group. *Med Lav.* 2005 Jul-Aug;96(4):360-9.

PMID: 16457433.

37.Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, Hausner P, Kennedy R, Kindler H, Metintas M, **Mutti L**, Onda M, Pass H, Premkumar A, Roggli V, Sterman D, Sugarbaker P, Taub R, Verschraegen C. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. *Ann Oncol.* 2006 Nov;17(11):1615-9. doi: 10.1093/annonc/mdl060. Epub 2006 Apr 6. PMID: 16600983.

38.Porta C, **Mutti L**, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. *Cancer Chemother Pharmacol.* 2007 Jan;59(1):149-50. doi: 10.1007/s00280-006-0243-4.

Epub 2006 Apr 25. PMID: 16636799.

39.Landi S, Gemignani F, Neri M, Barale R, Bonassi S, Bottari F, Canessa PA, Canzian F, Ceppi M, Filiberti R, Ivaldi GP, Mencoboni M, Scaruffi P, Tonini GP, **Mutti L**, Puntoni R. Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. *Int J Cancer.* 2007 Jun 15;120(12):2739-43. doi: 10.1002/ijc.22590. PMID: 17290392.

40.Bertino P, Marconi A, Palumbo L, Bruni BM, Barbone D, Germano S, Dogan AU, Tassi GF, Porta C, **Mutti L**, Gaudino G. Erionite and asbestos differently cause transformation of human mesothelial cells. *Int J Cancer.* 2007 Jul 1;121(1):12-20. doi: 10.1002/ijc.22687. PMID: 17354240.

41.Simonini S, Foddìs R, Filiberti R, Puntoni R, **Mutti L**, Ambrosino N, Chella A, Guglielmi G, Buselli R, Iuzzolini M, Mignani A, Ottenga F, Cristaudo A. Valutazione di dosaggi seriati di mesotelina sierica in pazienti affetti da mesotelioma maligno della pleura [Evaluation of a series of serum mesothelin in patients with pleural malignant mesothelioma]. *G Ital Med Lav Ergon.* 2007 Jul-Sep;29(3 Suppl):339-42. Italian. PMID: 18409715.

42.Foddìs R, Vivaldi A, Filiberti R, Puntoni R, **Mutti L**, Ambrosino N, Chella A, Guglielmi G, Gattini V, Buselli R, Perretta S, Cristaudo A. Il dosaggio della mesotelina sierica nel follow-up dei lavoratori ex esposti ad amianto [Serum mesothelin dosages in follow-up of previously exposed workers]. *G Ital Med Lav Ergon.* 2007 Jul-Sep;29(3 Suppl):342-5. Italian. PMID: 18409716.

43.Bertino P, Porta C, Barbone D, Germano S, Busacca S, Pinato S, Tassi G, Favoni R, Gaudino G, **Mutti L.** Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. *Thorax*. 2007

Aug;62(8):690-5. doi: 10.1136/thx.2006.069872. Epub 2007 Feb 20. PMID: 17311837; PMCID: PMC2117287.

- 44.**Cristaudo A, Foddìs R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, **Mutti L**, Puntoni R. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. *Clin Cancer Res.* 2007 Sep 1;13(17):5076-81. doi: 10.1158/1078-0432.CCR-07-0629. PMID: 17785560.
- 45.**Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, **Mutti L**. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. *Clin Cancer Res.* 2007 Oct 1;13(19):5942-51. doi: 10.1158/1078-0432.CCR-07-0536. Erratum in: *Clin Cancer Res.* 2007 Nov 1;13(21):6543. PMID: 17908991.
- 46.**Bertino P, Piccardi F, Porta C, Favoni R, Cilli M, **Mutti L**, Gaudino G. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. *Clin Cancer Res.* 2008 Jan 15;14(2):541-8. doi: 10.1158/1078-0432.CCR-07-1388. PMID: 18223230.
- 52.**Fennell DA, Chacko A, **Mutti L**. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. *Oncogene.* 2008 Feb 21;27(9):1189-97. doi: 10.1038/sj.onc.1210744. Epub 2007 Sep 10. PMID: 17828309.
- 53.**Ugolini D, Neri M, Ceppi M, Cesario A, Dianzani I, Filiberti R, Gemignani F, Landi S, Magnani C, **Mutti L**, Puntoni R, Bonassi S. Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factor. *Mutat Res.* 2008 Mar-Apr;658(3):162-71. doi: 10.1016/j.mrrev.2007.08.001. Epub 2007 Aug 10. PMID: 17904414.
- 54.**Fennell DA, Gaudino G, O'Byrne KJ, **Mutti L**, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. *Nat Clin Pract Oncol.* 2008 Mar;5(3):136-47. doi: 10.1038/ncponc1039. PMID: 18227828.
- 55.**Neri M, Ugolini D, Dianzani I, Gemignani F, Landi S, Cesario A, Magnani C, **Mutti L**, Puntoni R, Bonassi S. Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. *Mutat Res.* 2008 Jul-Aug;659(1-2):126-36. doi: 10.1016/j.mrrev.2008.02.002. Epub 2008 Feb 23. PMID: 18420450.
- 56.**Porta C, Paglino C, **Mutti L**. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. *Biologics.* 2008 Dec;2(4):601-9. doi: 10.2147/btt.s2383. PMID: 19707441; PMCID: PMC2727885.
- 57.**Pancaldi C, Balatti V, Guaschino R, Vaniglia F, Corallini A, Martini F, **Mutti L**, Tognon M. Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution. *J Infect.* 2009 Jan;58(1):53-60. doi: 10.1016/j.jinf.2008.10.014. Epub 2008 Dec 13. PMID: 19070904.
- 58.**Gray SG, Fennell DA, **Mutti L**, O'Byrne KJ. In arrayed ranks: array technology in the study of mesothelioma. *J Thorac Oncol.* 2009 Mar;4(3):411-25. doi: 10.1097/JTO.0b013e3181951ce8. PMID: 19247089.

59. Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G,

Mutti L,

Moro L. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.

Cancer Res. 2009 Jun 1;69(11):4598-604. doi: 10.1158/0008-5472.CAN-08-4523. PMID: 19487281.

- 60.**Belli C, Fennell D, Giovannini M, Gaudino G, **Mutti L**. Malignant pleural mesothelioma: current treatments and emerging drugs. *Expert Opin Emerg Drugs*. 2009 Sep;14(3):423-37. doi: 10.1517/14728210903074563. PMID: 19552609.
- 61.**Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta C, **Mutti L**, Gaudino G. Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. *Eur Respir J*. 2009 Dec;34(6):1399-407. doi: 10.1183/09031936.00102308. Epub 2009 May 21. PMID: 19460788.
- 62.**Gemignani F, Neri M, Bottari F, Barale R, Canessa PA, Canzian F, Ceppi M, Spitaleri I, Cipollini M, Ivaldi GP, Mencoboni M, Scaruffi P, Tonini GP, Ugolini D, **Mutti L**, Bonassi S, Landi S. Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism. *Mutat Res*. 2009 Dec 1;671(1-2):76-83. doi: 10.1016/j.mrfmmm.2009.09.003. Epub 2009 Sep 12. PMID: 19751749.
- 63.**Belli C, Anand S, Panella M, Giovannini M, Tassi G, Fennell D, **Mutti L**. Will antiangiogenic agents be a future for mesothelioma therapy? *Curr Med Chem*. 2010;17(27):3069-79. doi: 10.2174/092986710791959710. PMID: 20629625.
- 64.**Melotti A, Daga A, Marubbi D, Zunino A, **Mutti L**, Corte G. In vitro and in vivo characterization of highly purified human mesothelioma derived cells. *BMC Cancer*. 2010 Feb 22;10:54. doi: 10.1186/1471-2407-10-54. PMID: 20175889; PMCID: PMC2850899.
- 65.**Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, **Mutti L**, Pierotti M, Gaudino G. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. *Am J Respir Cell Mol Biol*. 2010 Mar;42(3):312-9. doi: 10.1165/rcmb.2009-0060OC. Epub 2009 Jun 5. PMID: 19502386.
- 66.**Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le Péchoux C, **Mutti L**, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W; European Respiratory Society/European Society of Thoracic Surgeons Task Force. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. *Eur Respir J*. 2010 Mar;35(3):479-95. doi: 10.1183/09031936.00063109. Epub 2009 Aug 28. PMID: 19717482.
- 67.**Favoni RE, Pattarozzi A, Lo Casto M, Barbieri F, Gatti M, Paleari L, Bajetto A, Porcile C, Gaudino G, **Mutti L**, Corte G, Florio T. Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation. *Curr Cancer Drug Targets*. 2010 Mar;10(2):176-91. doi: 10.2174/156800910791054130. PMID: 20088784.
- 68.**Belli C, Anand S, Tassi G, Fennell D, **Mutti L**. Translational therapies for malignant pleural mesothelioma. *Expert Rev Respir Med*. 2010 Apr;4(2):249-60. doi: 10.1586/ers.10.17. PMID: 20406091.
- 69.**Cristaudo A, Foddìs R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G,

Ambrosino N, Canessa PA, Chella A, Lucchi M, Mussi A, **Mutti L.** Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.

Int J Biol Markers. 2010 Jul-Sep;25(3):164-70. doi:
10.1177/172460081002500307. PMID: 20878622.

- 70.**Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le Pe'choux C, **Mutti L**, Paireon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W; European Respiratory Society; European Society of Thoracic Surgeons. [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]. Zhongguo Fei Ai Za Zhi. 2010 Oct;13(10):C23-45. Chinese. doi: 10.3779/j.issn.1009-3419.2010.10.14. PMID: 20976998; PMCID: PMC6134413.
- 71.**Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le Pe'choux C, **Mutti L**, Paireon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W; European Respiratory Society; European Society of Thoracic Surgeons. [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]. Zhongguo Fei Ai Za Zhi. 2010 Oct;13(10):C23-45. Chinese. doi: 10.3779/j.issn.1009-3419.2010.10.14. PMID: 20976998; PMCID: PMC6134413.
- 72.**Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J, Giroux DJ, Hasegawa S, Kernstine KH, Waller D, Rami-Porta R; International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol. 2011 Aug;6(8):1304-12. doi: 10.1097/JTO.0b013e3182208e3f. PMID: 21847060.
- 73.**Calabrò L, Sigalotti L, Fonsatti E, Bertocci E, Di Giacomo AM, Danielli R, Cutaia O, Colizzi F, Covre A, **Mutti L**, Natali PG, Maio M. Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications. J Cell Physiol. 2011 Oct;226(10):2595-600. doi: 10.1002/jcp.22600. PMID: 21792917.
- 74.**Jennings CJ, O'Grady A, Cummins R, Murer B, Al-Alawi M, Madden SF, **Mutti L**, Harvey BJ, Thomas W, Kay EW. Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma. J Thorac Oncol. 2012 Jan;7(1):243-8. doi: 10.1097/JTO.0b013e31822f6544. PMID: 22011668.
- 75.**Pinton G, Manente AG, Angeli G, **Mutti L**, Moro L. Perifosine as a potential novel anti- cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. PLoS One. 2012;7(5):e36856. doi: 10.1371/journal.pone.0036856. Epub 2012 May 10. PMID: 22590625; PMCID: PMC3349630.
- 76.**Neri M, Ugolini D, Boccia S, Canessa PA, Cesario A, Leoncini G, **Mutti L**, Bonassi S. Chemoprevention of asbestos-linked cancers: a systematic review. Anticancer Res. 2012 Mar;32(3):1005-13. PMID: 22399624.
- 77.**Pinton G, Manente AG, Moro L, **Mutti L**. Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma. Expert Opin Med Diagn. 2012 May;6(3):171-3. doi: 10.1517/17530059.2012.676042. PMID: 23480683.

78.Ranzato E, Martinotti S, Magnelli V, Murer B, Biffo S, **Mutti L**, Burlando B.
Epigallocatechin-3-gallate induces mesothelioma cell death via H₂O₂-dependent T-type

Ca²⁺ channel opening. *J Cell Mol Med*. 2012 Nov;16(11):2667-78. doi: 10.1111/j.1582-4934.2012.01584.x. PMID: 22564432; PMCID: PMC4118235.

79.Blayne JK, Ceresoli GL, Castagneto B, O'Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, Busacca S, Porta C, **Mutti L**, O'Byrne KJ, Scullin P, Gaafar R, Baas P, Van Meerbeeck J, Fennell DA. Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. *Eur J Cancer*. 2012 Nov;48(16):2983-92. doi: 10.1016/j.ejca.2012.05.018. Epub 2012 Jun 15. PMID: 22704893.

80.Volta V, Ranzato E, Martinotti S, Gallo S, Russo MV, **Mutti L**, Biffo S, Burlando B. Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma. *PLoS One*. 2013;8(3):e58051. doi: 10.1371/journal.pone.0058051. Epub 2013 Mar 6. PMID: 23526965; PMCID: PMC3590277.

81.Pinton G, Manente AG, Murer B, De Marino E, **Mutti L**, Moro L. PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. *J Cell Mol Med*. 2013 Feb;17(2):233-41. doi: 10.1111/jcmm.12000. Epub 2013 Jan 10. PMID: 23301673; PMCID: PMC3822586.

82.Busacca S, Chacko AD, Klabatsa A, Arthur K, Sheaff M, Barbone D, **Mutti L**, Gunasekharan VK, Gorski JJ, El-Tanani M, Broaddus VC, Gaudino G, Fennell DA. BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma. *PLoS One*. 2013 Jun 7;8(6):e65489. doi: 10.1371/journal.pone.0065489.

Erratum in: *PLoS One*. 2013;8(12). doi:10.1371/annotation/90879c69-ebc5-40b2-9926-4a00e4f9e055. Barbone, Dario [added]; Mutti, Luciano [added]. PMID: 23762382; PMCID: PMC3676324.

83.Manente AG, Valenti D, Pinton G, Jithesh PV, Daga A, Rossi L, Gray SG, O'Byrne KJ, Fennell DA, Vacca RA, Nilsson S, **Mutti L**, Moro L. Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. *Oncogenesis*. 2013 Sep 23;2(9):e72. doi: 10.1038/oncsis.2013.32. PMID: 24061575; PMCID: PMC3816222.

84.Pinton G, Manente AG, Tavian D, Moro L, **Mutti L**. Therapies currently in Phase II trials for malignant pleural mesothelioma. *Expert Opin Investig Drugs*. 2013 Oct;22(10):1255-63. doi: 10.1517/13543784.2013.816281. Epub 2013 Jul 2. PMID: 23815672.

85.Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, **Mutti L**, Maio M. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

Lancet Oncol. 2013 Oct;14(11):1104-1111. doi: 10.1016/S1470-2045(13)70381-4. Epub 2013 Sep 11. PMID: 24035405.

86.Valenti D, de Bari L, Manente GA, Rossi L, **Mutti L**, Moro L, Vacca RA. Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells. *Biochim Biophys Acta*. 2013 Dec;1832(12):2085-96. doi: 10.1016/j.bbadis.2013.07.014. Epub 2013 Aug 2.

PMID: 23911347.

87.Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, **Mutti L**, Barale R, Gemignani F, Giamas G, Landi S. MSLN gene silencing has an anti- malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. PLoS One. 2014 Jan 21;9(1):e85935. doi: 10.1371/journal.pone.0085935.

Erratum in: PLoS One. 2017 Jun 22;12(6):e0180317. doi: 10.1371/journal.pone.0180317. PMID: 24465798; PMCID: PMC3897543.

- 88.**Garritano S, De Santi C, Silvestri R, Melaiu O, Cipollini M, Barone E, Lucchi M, Barale R, **Mutti L**, Gemignani F, Bonotti A, Foddìs R, Cristaudo A, Landi S. A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people. *J Thorac Oncol*. 2014 Nov;9(11):1662-8. doi: 10.1097/JTO.0000000000000322. PMID: 25436799.
- 89.**Melaiu O, Melissari E, **Mutti L**, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddìs R, Lucchi M, Pellegrini S, Gemignani F, Landi S. Expression status of candidate genes in mesothelioma tissues and cell lines. *Mutat Res*. 2015 Jan;771:6-12. doi: 10.1016/j.mrfmmm.2014.11.002. Epub 2014 Nov 13. PMID: 25771974.
- 90.**Guazzelli A, Hussain M, Krstic-Demonacos M, **Mutti L**. Tremelimumab for the treatment of malignant mesothelioma. *Expert Opin Biol Ther*. 2015;15(12):1819-29. doi: 10.1517/14712598.2015.1116515. PMID: 26560442.
- 91.**Miluzio A, Oliveto S, Pesce E, **Mutti L**, Murer B, Grosso S, Ricciardi S, Brina D, Biffo S. Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo. *Oncotarget*. 2015 Nov 10;6(35):37471-85. doi: 10.18632/oncotarget.5462. PMID: 26462016; PMCID: PMC4741942.
- 92.**Bakker E, Qattan M, **Mutti L**, Demonacos C, Krstic-Demonacos M. The role of microenvironment and immunity in drug response in leukemia. *Biochim Biophys Acta*. 2016 Mar;1863(3):414-426. doi: 10.1016/j.bbamcr.2015.08.003. Epub 2015 Aug 6. PMID: 26255027.
- 93.**Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, **Mutti L**, Landi S. Targeting hypoxic response for cancer therapy. *Oncotarget*. 2016 Mar 22;7(12):13464-78. doi: 10.18632/oncotarget.7229. PMID: 26859576; PMCID: PMC4924654.
- 94.**Fiorillo M, Lamb R, Tanowitz HB, **Mutti L**, Krstic-Demonacos M, Cappello AR, Martinez- Otschoorn UE, Sotgia F, Lisanti MP. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. *Oncotarget*. 2016 Jun 7;7(23):34084-99. doi: 10.18632/oncotarget.9122. PMID: 27136895; PMCID: PMC5085139.
- 95.**Oliver LC, Welch L, Frank AL, Lemen RA, **Mutti L**. New standard for assessing asbestos exposure and its consequences? *Occup Environ Med*. 2016 Oct;73(10):709-10. doi: 10.1136/oemed-2016-103693. Epub 2016 Jul 27. PMID: 27466614.
- 96.**Nabavi N, Bennewith KL, Churg A, Wang Y, Collins CC, **Mutti L**. Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. *Genes Cancer*. 2016 Nov;7(11- 12):340-354. doi: 10.18632/genesandcancer.124. PMID: 28191281; PMCID: PMC5302036.
- 97.**Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddìs R, Cristaudo A, **Mutti L**, Fontanini G, Gemignani F, Landi S. Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib

besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. *Genes Cancer*. 2017 Jan;8(1-2):438-452. doi: 10.18632/genesandcancer.129. PMID: 28435517; PMCID: PMC5396622.

- 98.**Guazzelli A, Bakker E, Krstic-Demonacos M, Lisanti MP, Sotgia F, **Mutti L**. Anti-CTLA-4 therapy for malignant mesothelioma. *Immunotherapy*. 2017 Mar;9(3):273-280. doi: 10.2217/imt-2016-0123. PMID: 28231719.
- 99.**Pattarozzi A, Carra E, Favoni RE, Würth R, Marubbi D, Filiberti RA, **Mutti L**, Florio T, Barbieri F, Daga A. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. *Stem Cell Res Ther*. 2017 May 25;8(1):119. doi: 10.1186/s13287-017-0573-7. PMID: 28545562; PMCID: PMC5445511.
- 100.**De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, Vymetalkova V, Barone E, Paolicchi E, Corrado A, Lepori I, Dell'Anno I, Pellè L, Vodicka P, **Mutti L**, Foddis R, Cristaudo A, Gemignani F, Landi S. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals. *Occup Environ Med*. 2017 Jun;74(6):456-463. doi: 10.1136/oemed-2016-104024. Epub 2017 Mar 25. PMID: 28343162.
- 101.**Qattan MY, Bakker EY, Rajendran R, Chen DW, Saha V, Liu J, Zeef L, Schwartz JM, **Mutti L**, Demonacos C, Krstic-Demonacos M. Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia. *PLoS One*. 2017 Jun 5;12(6):e0178606. doi: 10.1371/journal.pone.0178606. PMID: 28582465; PMCID: PMC5459454.
- 102.**De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddis R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, **Mutti L**, Landi S. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. *Sci Rep*. 2017 Jun 9;7(1):3140. doi: 10.1038/s41598-017-02694-0. PMID: 28600498; PMCID: PMC5466648.
- 103.**Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, **Mutti L**, Barale R, Gemignani F, Giamas G, Landi S. Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. *PLoS One*. 2017 Jun 22;12(6):e0180317. doi: 10.1371/journal.pone.0180317. Erratum for: *PLoS One*. 2014 Jan 21;9(1):e85935. doi: 10.1371/journal.pone.0085935. PMID: 28640856; PMCID: PMC5481151.
- 104.**Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, **Mutti L**. Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. *Expert Opin Investig Drugs*. 2017 Aug;26(8):933-944. doi: 10.1080/13543784.2017.1351545. Epub 2017 Jul 12. PMID: 28679291.
- 105.**Bakker E, Guazzelli A, Ashtiani F, Demonacos C, Krstic-Demonacos M, **Mutti L**. Immunotherapy advances for mesothelioma treatment. *Expert Rev Anticancer Ther*. 2017 Sep;17(9):799-814. doi: 10.1080/14737140.2017.1358091. Epub 2017 Jul 31. PMID: 28724330.
- 106.**Bakker E, Tian K, **Mutti L**, Demonacos C, Schwartz JM, Krstic-Demonacos M. Insight into glucocorticoid receptor signalling through interactome model analysis. *PLoS Comput Biol*. 2017 Nov 6;13(11):e1005825. doi: 10.1371/journal.pcbi.1005825. PMID: 29107989; PMCID: PMC5690696.
- 108.**Ricciardi S, Cardillo G, Zirafa CC, Carleo F, Facciolo F, Fontanini G, **Mutti L**,

Melfi F. Surgery for malignant pleural mesothelioma: an international guidelines review. J Thorac

Dis. 2018 Jan;10(Suppl 2):S285-S292. doi: 10.21037/jtd.2017.10.16. PMID: 29507797; PMCID: PMC5830571.

- 109.Mutti L**, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. *J Thorac Oncol*. 2018 Sep;13(9):1269-1283. doi: 10.1016/j.jtho.2018.06.011. PMID: 29966799; PMCID: PMC6643278.
- 110.**Tian K, Bakker E, Hussain M, Guazzelli A, Alhebshi H, Meysami P, Demonacos C, Schwartz JM, **Mutti L**, Krstic-Demonacos M. p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification. *J Transl Med*. 2018 Oct 13;16(1):282. doi: 10.1186/s12967-018-1650-0. PMID: 30316293; PMCID: PMC6186085.
- 111.**Oliveto S, Alfieri R, Miluzio A, Scagliola A, Secli RS, Gasparini P, Grosso S, Cascione L, **Mutti L**, Biffo S. A Polysome-Based microRNA Screen Identifies miR-24-3p as a Novel Promigratory miRNA in Mesothelioma. *Cancer Res*. 2018 Oct 15;78(20):5741-5753. doi: 10.1158/0008-5472.CAN-18-0655. Epub 2018 Aug 2. PMID: 30072395; PMCID: PMC6193539.
- 112.**Rich AL, Baldwin DR, Beckett P, Berghmans T, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hansen NG, Hardavella G, Jakobsen E, Jovanovic D, Konsoulova A, Massard G, McPhelim J, Meert AP, Milroy R, **Mutti L**, Paesmans M, Peake MD, Putora PM, de Ruysscher DKM, Sculier JP, Scherpereel A, Subotic DR, Van Schil P, Blum TG. ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe. *Eur Respir J*. 2018 Dec 20;52(6):1800610. doi: 10.1183/13993003.00610-2018. PMID: 30361252.
- 113.**Guazzelli A, Meysami P, Bakker E, Demonacos C, Giordano A, Krstic-Demonacos M, **Mutti L**. *BAP1* Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment. *Int J Mol Sci*. 2019 Jan 19;20(2):429. doi: 10.3390/ijms20020429. PMID: 30669483; PMCID: PMC6359027.
- 114.**Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raepffel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, **Mutti L**, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG. When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All? *Front Endocrinol (Lausanne)*. 2019 Feb 26;10:89. doi: 10.3389/fendo.2019.00089. PMID: 30863365; PMCID: PMC6399142.
- 115.**Albelazi MS, Martin PR, Mohammed S, **Mutti L**, Parsons JL, Elder RH. The Biochemical Role of the Human NEIL1 and NEIL3 DNA Glycosylases on Model DNA Replication Forks. *Genes (Basel)*. 2019 Apr 23;10(4):315. doi: 10.3390/genes10040315. PMID: 31018584; PMCID: PMC6523847.
- 116.**Guazzelli A, Meysami P, Bakker E, Bonanni E, Demonacos C, Krstic-Demonacos M, **Mutti L**. What can independent research for mesothelioma achieve to treat this orphan disease? *Expert Opin Investig Drugs*. 2019 Aug;28(8):719-732. doi: 10.1080/13543784.2019.1638363. Epub 2019 Jul 1. PMID: 31262194.
- 117.**Garva R, Thepmalee C, Yasamut U, Sudsaward S, Guazzelli A, Rajendran R,

Tongmuang N, Khunchai S, Meysami P, Limjindaporn T, Yenchitsomanus PT, **Mutti L**, Krstic-Demonacos M, Demonacos C. Sirtuin Family Members Selectively Regulate Autophagy in

Osteosarcoma and Mesothelioma Cells in Response to Cellular Stress. *Front Oncol.* 2019 Sep 24;9:949. doi: 10.3389/fonc.2019.00949. PMID: 31608237; PMCID: PMC6771295.

118.Barbarino M, Bottaro M, Luzzi L, Giordano A, **Mutti L.** Tumour Treating Fields for mesothelioma. *Lancet Oncol.* 2020 Jan;21(1):e8. doi: 10.1016/S1470-2045(19)30829-0. PMID: 31908312.

119.Gray SG, **Mutti L.** Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. *Transl Lung Cancer Res.* 2020 Feb;9(Suppl 1):S100- S119. doi: 10.21037/tlcr.2019.11.23. PMID: 32206576; PMCID: PMC7082257.

120.Barbarino M, Cesari D, Bottaro M, Luzzi L, Namagerdi A, Bertolino FM, Bellan C, Proietti F, Somma P, Micheli M, de Santi MM, Guazzo R, **Mutti L,** Pirtoli L, Paladini P, Indovina P, Giordano A. PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach. *J Cell Mol Med.* 2020 May;24(10):5565- 5577. doi: 10.1111/jcmm.15213. Epub 2020 Apr 17. PMID: 32301278; PMCID: PMC7214180.

121.**Mutti L,** Pentimalli F, Baglio G, Maiorano P, Saladino RE, Correale P, Giordano A. Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate? *Front Immunol.* 2020 May 28;11:1208. doi: 10.3389/fimmu.2020.01208. PMID: 32574270; PMCID: PMC7270396.

122.Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruyscher D, Durieux V, Faivre-Finn C, Fennell D, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, **Mutti L,** Pairon JC, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Cardillo G, Putora PM. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. *Eur Respir J.* 2020 Jun 11;55(6):1900953. doi: 10.1183/13993003.00953- 2019. PMID: 32451346.

123.Opitz I, Scherpereel A, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruyscher D, Durieux V, Faivre-Finn C, Fennell DA, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, **Mutti L,** Pairon JC, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Putora PM, Cardillo

G. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. *Eur J Cardiothorac Surg.* 2020 Jul 1;58(1):1-24. doi: 10.1093/ejcts/ezaa158. PMID: 32448904.

124.Correale P, **Mutti L,** Pentimalli F, Baglio G, Saladino RE, Sileri P, Giordano A. HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy. *Int J Mol Sci.* 2020 Jul 23;21(15):5205. doi: 10.3390/ijms21155205. PMID: 32717807; PMCID: PMC7432860.

125.Correale P, Saladino RE, Giannarelli D, Sergi A, Mazzei MA, Bianco G, Giannicola R, Iuliano E, Forte IM, Calandruccio ND, Falzea AC, Strangio A, Nardone V, Pastina P, Tini P, Luce A, Caraglia M, Caracciolo D, **Mutti L,** Tassone P, Pirtoli L, Giordano A, Tagliaferri P. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. *Cells.* 2020 Aug 25;9(9):1964. doi: 10.3390/cells9091964. PMID: 32854442; PMCID: PMC7564884.

126.Sudsaward S, Khunchai S, Thepmalee C, Othman A, Limjindaporn T, Yenchitsomanus PT, **Mutti L**, Krstic-Demonacos M, Demonacos C. Endoplasmic reticulum stress, unfolded protein response and autophagy contribute to resistance to glucocorticoid treatment in

human acute lymphoblastic leukaemia cells. *Int J Oncol.* 2020 Sep;57(3):835-844. doi: 10.3892/ijo.2020.5089. Epub 2020 Jun 26. PMID: 32705154.

127.Dell'Anno I, Barone E, **Mutti L**, Rassl DM, Marciniak SJ, Silvestri R, Landi S, Gemignani

F. Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report). *J Transl Med.* 2020 Sep 4;18(1):341. doi: 10.1186/s12967-020-02487-6. PMID: 32887638; PMCID: PMC7650278.

128.Costa C, Indovina P, Mattioli E, Forte IM, Iannuzzi CA, Luzzi L, Bellan C, De Summa S, Bucci E, Di Marzo D, De Feo M, **Mutti L**, Pentimalli F, Giordano A. P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma. *Cell Death Dis.* 2020 Sep 14;11(9):748. doi: 10.1038/s41419-020-02940-w. Erratum in: *Cell Death Dis.* 2020 Oct 16;11(10):867. doi: 10.1038/s41419-020-03016-5. PMID: 32929059; PMCID: PMC7490273.

129.Costa C, Indovina P, Mattioli E, Forte IM, Iannuzzi CA, Luzzi L, Bellan C, De Summa S, Bucci E, Di Marzo D, De Feo M, **Mutti L**, Pentimalli F, Giordano A. Correction: P53- regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma. *Cell Death Dis.* 2020 Oct 16;11(10):867. doi: 10.1038/s41419-020-03016-5. Erratum for: *Cell Death Dis.* 2020 Sep 14;11(9):748. doi: 10.1038/s41419-020-02940-w. PMID: 33067416; PMCID: PMC7567790.

130.Alhammad R, Khunchai S, Tongmuang N, Limjindaporn T, Yenchitsomanus PT, **Mutti L**, Krstic-Demonacos M, Demonacos C. Protein disulfide isomerase A1 regulates breast cancer cell immunorecognition in a manner dependent on redox state. *Oncol Rep.* 2020 Dec;44(6):2406-2418. doi: 10.3892/or.2020.7816. Epub 2020 Oct 20. PMID: 33125139; PMCID: PMC7610313.

131.Ge X, Zhang Z, Zhang S, Yuan F, Zhang F, Yan X, Han X, Ma J, Wang L, Tao H, Li X, Zhi X, Huang Z, Hofman P, Prelaj A, Banna GL, **Mutti L**, Hu Y, Wang J. Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. *Transl Lung Cancer Res.* 2020 Dec;9(6):2391-2400. doi: 10.21037/tlcr-20-1252. PMID: 33489801; PMCID: PMC7815351.

132.Morani F, Bisceglia L, Rosini G, **Mutti L**, Melaiu O, Landi S, Gemignani F. Identification of Overexpressed Genes in Malignant Pleural Mesothelioma. *Int J Mol Sci.* 2021 Mar 8;22(5):2738. doi: 10.3390/ijms22052738. PMID: 33800494; PMCID: PMC7962966.

133.Correale P, Pentimalli F, Baglio G, Krstic-Demonacos M, Saladino RE, Giordano A, **Mutti L**. Is There Already a Need of Reckoning on Cancer Immunotherapy? *Front Pharmacol.* 2021 Mar 26;12:638279. doi: 10.3389/fphar.2021.638279. PMID: 33841155; PMCID: PMC8033763.

134.Moretti G, Aretini P, Lessi F, Mazzanti CM, Ak G, Metintas M, Lando C, Filiberti RA, Lucchi M, Bonotti A, Foddis R, Cristaudo A, Bottari A, Apollo A, Del Re M, Danesi R, **Mutti L**, Gemignani F, Landi S. Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study. *Cancers (Basel).* 2021 May 18;13(10):2445. doi: 10.3390/cancers13102445. PMID: 34070018; PMCID: PMC8157824.

135.Nardone V, Giannicola R, Bianco G, Giannarelli D, Tini P, Pastina P, Falzea AC, Macheda S, Caraglia M, Luce A, Zappavigna S, **Mutti L**, Pirtoli L, Giordano A,

Correale P. Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small- Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade. Front

Oncol. 2021 Jun 14;11:684110. doi: 10.3389/fonc.2021.684110. PMID: 34195086; PMCID: PMC8236817.

- 136.**Nardone V, Barbarino M, Angrisani A, Correale P, Pastina P, Cappabianca S, Reginelli A, **Mutti L**, Miracco C, Giannicola R, Giordano A, Pirtoli L. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy. *Int J Mol Sci.* 2021 Aug 4;22(16):8391. doi: 10.3390/ijms22168391. PMID: 34445095; PMCID: PMC8395054.
- 137.**Nardone V, Giannicola R, Giannarelli D, Saladino RE, Azzarello D, Romeo C, Bianco G, Rizzo MR, Di Meo I, Nesci A, Pastina P, Falzea AC, Caracciolo D, Reginelli A, Caraglia M, Luce A, **Mutti L**, Giordano A, Cappabianca S, Pirtoli L, Barbieri V, Tassone P, Tagliaferri P, Correale P. Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. *Life (Basel).* 2021 Nov 15;11(11):1235. doi: 10.3390/life11111235. PMID: 34833111; PMCID: PMC8621400.
- 138.**Porta C, Nardone V, Gray SG, Correale P, **Mutti L**. RAMES study: is there really a role for VEGF inhibition in mesothelioma? *Lancet Oncol.* 2021 Dec;22(12):e532. doi: 10.1016/S1470-2045(21)00640-9. PMID: 34856142.
- 139.**Alhebshi H, Tian K, Patnaik L, Taylor R, Bezecny P, Hall C, Muller PAJ, Safari N, Creamer DPM, Demonacos C, **Mutti L**, Bittar MN, Krstic-Demonacos M. Evaluation of the Role of p53 Tumour Suppressor Posttranslational Modifications and TTC5 Cofactor in Lung Cancer. *Int J Mol Sci.* 2021 Dec 7;22(24):13198. doi: 10.3390/ijms222413198. PMID: 34947995; PMCID: PMC8707832.
- 140.**Pezzicoli G, Rizzo M, Perrone M, Minei S, **Mutti L**, Porta C. A Glimpse in the Future of Malignant Mesothelioma Treatment. *Front Pharmacol.* 2021 Dec 15;12:809337. doi: 10.3389/fphar.2021.809337. PMID: 34975505; PMCID: PMC8714955.
- 141.**Correale P, Pentimalli F, Nardone V, Giordano A, **Mutti L**. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? *Lancet Oncol.* 2022 Jan;23(1):e13. doi: 10.1016/S1470-2045(21)00702-6. PMID: 34973223.
- 142.**Nardone V, Correale P, **Mutti L**, Desideri I, Romeo C, Pastina P, Tagliaferri P, Caraglia M, Reginelli A, Pirtoli L, Cappabianca S. Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point? *J Thorac Oncol.* 2022 Feb;17(2):e10-e12. doi: 10.1016/j.jtho.2021.09.019. PMID: 35074228.
- 143.**Meirson T, Pentimalli F, Cerza F, Baglio G, Gray SG, Correale P, Krstic-Demonacos M, Markel G, Giordano A, Bomze D, **Mutti L**. Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma. *JAMA Netw Open.* 2022 Mar 1;5(3):e221490. doi: 10.1001/jamanetworkopen.2022.1490. PMID: 35262715; PMCID: PMC8908075.
- 144.**Chen X, Guo J, Zhou F, Ren W, Pu J, **Mutti L**, Niu X, Jiang X. Over-Expression of Long Non-Coding RNA-AC099850.3 Correlates With Tumor Progression and Poor Prognosis in Lung Adenocarcinoma. *Front Oncol.* 2022 May 11;12:895708. doi: 10.3389/fonc.2022.895708. PMID: 35646670;

PMCID: PMC9132095.

145.Dell'Anno I, Melani A, Martin SA, Barbarino M, Silvestri R, Cipollini M, Giordano A, **Mutti L**, Nicolini A, Luzzi L, Aiello R, Gemignani F, Landi S. A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma. *Cancers (Basel)*. 2022 May 20;14(10):2527. doi: 10.3390/cancers14102527. PMID: 35626133; PMCID: PMC9139775.

- 146.**Nardone V, Porta C, Giannicola R, Correale P, **Mutti L**. Abemaciclib for malignant pleural mesothelioma. *Lancet Oncol*. 2022 Jun;23(6):e237. doi: 10.1016/S1470-2045(22)00276-5. PMID: 35654054.
- 147.**Bomze D, **Mutti L**, Goldman A, Markel G, Meirson T. Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy. *Lancet Oncol*. 2022 Jun;23(6):e245. doi: 10.1016/S1470-2045(22)00258-3. PMID: 35654062.
- 148.**Jiang X, Chen X, Guo J, Zhou F, Pu J, **Mutti L**, Niu X. Identification and Validation of lncRNA-AC087588.2 in Lung Adenocarcinoma: A Novel Prognostic and Diagnostic Indicator. *Front Mol Biosci*. 2022 Jun 13;9:923584. doi: 10.3389/fmolb.2022.923584. PMID: 35769906; PMCID: PMC9234292.
- 149.**Carbone M, Pass HI, Ak G, Alexander HR Jr, Baas P, Baumann F, Blakely AM, Bueno R, Bzura A, Cardillo G, Churpek JE, Dianzani I, De Rienzo A, Emi M, Emri S, Felley-Bosco E, Fennell DA, Flores RM, Grosso F, Hayward NK, Hesdorffer M, Hoang CD, Johansson PA, Kindler HL, Kittaneh M, Krausz T, Mansfield A, Metintas M, Minaai M, **Mutti L**, Nielsen M, O'Byrne K, Opitz I, Pastorino S, Pentimalli F, de Perrot M, Pritchard A, Ripley RT, Robinson B, Rusch V, Taioli E, Takinishi Y, Tanji M, Tsao AS, Tuncer AM, Walpole S, Wolf A, Yang H, Yoshikawa Y, Zolondick A, Schrupp DS, Hassan R. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. *J Thorac Oncol*. 2022 Jul;17(7):873-889. doi: 10.1016/j.jtho.2022.03.014. Epub 2022 Apr 21. PMID: 35462085; PMCID: PMC9233126.
- 150.**Ren W, Yuan Y, Chen X, Zhai H, An Y, Tang L, Wang J, Zhang D, Zhang L, Cheng W, Wang X, Duan L, **Mutti L**, Han B, Wang P. Identification and Validation of Long Non- Coding RNA LCIIAR as a Biomarker in LUAD. *Front Oncol*. 2022 Jul 4;12:933071. doi: 10.3389/fonc.2022.933071. PMID: 35860557; PMCID: PMC9293053.
- 151.**Fameli A, Nardone V, Shekarkar Azgomi M, Bianco G, Gandolfo C, Oliva BM, Monoriti M, Saladino RE, Falzea A, Romeo C, Calandruccio ND, Azzarello D, Giannicola R, Pirtoli L, Giordano A, Tassone P, Tagliaferri P, Cusi MG, **Mutti L**, Botta C, Correale P. PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non- small cell lung cancer patients: A single-cell flow cytometry approach. *Front Oncol*. 2022 Sep 14;12:911579. doi: 10.3389/fonc.2022.911579. PMID: 36185285; PMCID: PMC9515511.
- 152.**Ren W, Yuan Y, Peng J, **Mutti L**, Jiang X. The function and clinical implication of circular RNAs in lung cancer. *Front Oncol*. 2022 Oct 19;12:862602. doi: 10.3389/fonc.2022.862602. PMID: 36338714; PMCID: PMC9629004.
- 153.**Rossi E, **Mutti L**, Morrione A, Giordano A. Neuro-Immune Interactions in Severe COVID-19 Infection. *Pathogens*. 2022 Oct 29;11(11):1256. doi: 10.3390/pathogens11111256. PMID: 36365007; PMCID: PMC9699641.
- 154.**Meirson T, Nardone V, Pentimalli F, Markel G, Bomze D, D'Apolito M, Correale P, Giordano A, Pirtoli L, Porta C, Gray SG, **Mutti L**. Analysis of new

treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology. *J Transl Med.* 2022 Dec 13;20(1):593. doi: 10.1186/s12967-022-03744-6. PMID: 36514092; PMCID: PMC9749371.

- 155.**Ren W, Yuan Y, Li Y, **Mutti L**, Peng J, Jiang X. The function and clinical implication of YTHDF1 in the human system development and cancer. *Biomark Res.* 2023 Jan 17;11(1):5. doi: 10.1186/s40364-023-00452-1. PMID: 36650570; PMCID: PMC9847098.
- 156.**Blum TG, Morgan RL, Durieux V, Chorostowska-Wynimko J, Baldwin DR, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hardavella G, Hauptmann M, Jakobsen E, Jovanovic D, Knaut P, Massard G, McPhelim J, Meert AP, Milroy R, Muhr R, **Mutti L**, Paesmans M, Powell P, Putora PM, Rawlinson J, Rich AL, Rigau D, de Ruyscher D, Sculier JP, Schepereel A, Subotic D, Van Schil P, Tonia T, Williams C, Berghmans T. European Respiratory Society guideline on various aspects of quality in lung cancer care. *Eur Respir J.* 2023 Feb 16;61(2):2103201. doi: 10.1183/13993003.03201-2021. PMID: 36396145.
- 157.**Nardone V, Romeo C, D'Ippolito E, Pastina P, D'Apolito M, Pirtoli L, Caraglia M, **Mutti L**, Bianco G, Falzea AC, Giannicola R, Giordano A, Tagliaferri P, Vinciguerra C, Desideri I, Loi M, Reginelli A, Cappabianca S, Tassone P, Correale P. The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review. *Radiol Med.* 2023 Mar;128(3):316-329. doi: 10.1007/s11547-023-01602-z. Epub 2023 Feb 14. PMID: 36786970; PMCID: PMC10020247.
- 158.**Rahouma M, Baudo M, Zhang J, **Mutti L**. Editorial: Prognostic factors in non-small cell lung cancer. *Front Oncol.* 2023 Mar 14;13:1174625. doi: 10.3389/fonc.2023.1174625. PMID: 36998444; PMCID: PMC10043477.
- 159.**Pentimalli F, Krstic-Demonacos M, Costa C, **Mutti L**, Bakker EY. Intratumor microbiota as a novel potential prognostic indicator in mesothelioma. *Front Immunol.* 2023 Mar 14;14:1129513. doi: 10.3389/fimmu.2023.1129513. PMID: 36999042; PMCID: PMC10043377.
- 160.**Benvenuto M, Angiolini V, Focaccetti C, Nardozi D, Palumbo C, Carrano R, Rufini A, Bei R, Miele MT, Mancini P, Barillari G, Cirone M, Ferretti E, Tundo GR, **Mutti L**, Masuelli L, Bei R. Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo. *Biol Direct.* 2023 Apr 17;18(1):17. doi: 10.1186/s13062-023-00374-w. PMID: 37069690; PMCID: PMC10111665.
- 161.****Mutti L**, Gray SG. Editorial: Editor's challenge: Dr. Luciano Mutti - what is the true impact of ICIs on survival in the treatment of thoracic malignancies? *Front Oncol.* 2023 Sep 21;13:1285031. doi: 10.3389/fonc.2023.1285031. PMID: 37810979; PMCID: PMC10552561.
- 162.**Oliveto S, Ritter P, Deroma G, Miluzio A, Cordiglieri C, Benvenuti MR, **Mutti L**, Raimondi MT, Biffo S. The Impact of 3D Nichoids and Matrix Stiffness on Primary Malignant Mesothelioma Cells. *Genes (Basel).* 2024 Feb 1;15(2):199. doi: 10.3390/genes15020199. PMID: 38397189; PMCID: PMC10887956.
- 163.**Rahouma M, Mynard N, Baudo M, Khairallah S, Al-Thani S, Dabsha A, Shmushkevich S, Shoeib O, Hossny M, Eldeeb E, Aziz H, Abdelkarim N, Gaudino M, Mohamed A, Girardi L, Zhang J, **Mutti L**. Impact of Center Volume on Cardiopulmonary and Mortality Outcomes after Immune-Checkpoint

Inhibitors for Cancer: A Systematic Review and Meta-Analysis.
Cancers (Basel). 2024 Mar 13;16(6):1136. doi: 10.3390/cancers16061136. PMID:
38539471; PMCID: PMC10969050.

- 164.** Rigon M, **Mutti L**, Campanella M. Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer. *Mol Oncol.* 2024 Apr;18(4):797-814. doi: 10.1002/1878-0261.13591. Epub 2024 Mar 8. PMID: 38459714; PMCID: PMC10994233.
- 165.** Gray SG, Meirson T, **Mutti L**. Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma. *J Thorac Oncol.* 2024 Apr;19(4):541-546. doi: 10.1016/j.jtho.2024.01.016. PMID: 38582546.
- 166.** Dell'Anno I, Morani F, Patergnani S, Daga A, Pinton P, Giorgi C, **Mutti L**, Gemignani F, Landi S. Thonzonium bromide inhibits progression of malignant pleural mesothelioma through regulation of ERK1/2 and p38 pathways and mitochondrial uncoupling. *Cancer Cell Int.* 2024 Jun 29;24(1):226. doi: 10.1186/s12935-024-03400-7. PMID: 38951927; PMCID: PMC11218145.
- 167.** Gray SG, **Mutti L**, Meirson T. Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer. *J Thorac Oncol.* 2024 Aug;19(8):1125-1127. doi: 10.1016/j.jtho.2024.05.369. PMID: 39111996.
- 168.** Litterio M, Marchetti N, Carubbi F, Tudini M, **Mutti L**, Ferri C. Hepatic Sinusoidal Obstruction Syndrome (SOS) Associated with Checkpoint Inhibitor Therapy. *Eur J Case Rep Intern Med.* 2024 Dec 13;11(12):004885. doi: 10.12890/2024_004885. PMID: 39790842; PMCID: PMC11716309.
- 169.** Panuccio G, Correale P, d'Apolito M, **Mutti L**, Giannicola R, Pirtoli L, Giordano A, Labate D, Macheda S, Carabetta N, Abdelwahed YS, Landmesser U, Tassone P, Tagliaferri P, De Rosa S, Torella D. Immuno-related cardiovascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patients. *Basic Res Cardiol.* 2025 Feb;120(1):153-169. doi: 10.1007/s00395-024-01077-7. Epub 2024 Sep 3. PMID: 39225869; PMCID: PMC11790807.
- 170.** Gray SG, O'Connor D, **Mutti L**, Meirson T. Reducing pERKs to Break "RAS"istance to Sotorasib. *J Thorac Oncol.* 2025 Mar;20(3):259-261. doi: 10.1016/j.jtho.2025.01.002. PMID: 49766.
- 171.** Marampon F, Gravina GL, Cinelli E, Zaccaro L, Tomaciello M, Meglio ND, Gentili F, Cerase A, Perrella A, Yavorska M, Aburas S, **Mutti L**, Mazzei MA, Minniti G, Tini P. Reducing clinical target volume margins for multifocal glioblastoma: a multi-institutional analysis of patterns of recurrence and treatment response. *Radiat Oncol J.* 2024 Dec 19. doi: 10.3857/roj.2024.00059. Epub ahead of print. PMID: 39928965.
- 172.** Correale P, Baglio G, Parrella R, Saladino RE, Cuomo N, Scarano F, Francone M, Cuzzola M, Foti G, **Mutti L**, Pentimalli F, Giordano A. A rapid ecologic analysis, confirmed by a case-control study, identifies class I HLA alleles correlated to the risk of COVID-19. *J Transl Med.* 2025 Mar 10;23(1):303. doi: 10.1186/s12967-025-06285-w. PMID: 40065352; PMCID: PMC11892203.
- 173.** Marotto D, Martinelli C, Maiorano P, Fioravanti A, Amato P, Baglio G, Calugi G, Fiorillo A, Franchina T, Gimigliano F, Iolascon G, Maggio MC, **Mutti L**, Pirtoli L, Giordano A. Onco-rheumatology: from rags to riches, a transdisciplinary evolution. *Rheumatol Adv Pract.* 2025 May 9;9(2):rkaf053. doi: 10.1093/rap/rkaf053. PMID: 40496292; PMCID: PMC12150209.

174. Singh S, Raucci A, Glovi A, Iula G, **Mutti L**, De Laurentiis M, Giordano A, Cinti S. Socioeconomic impact of artificial intelligence-driven point-of-care testing devices for liquid biopsy in the OncoCheck system. *Cancer Metastasis Rev.* 2025 Aug 6;44(3):64. doi: 10.1007/s10555-025-10281-3. PMID: 40764849; PMCID: PMC12325499.
175. Carrano R, Zucca C, Cristina N, Grande M, Maggio EL, Bei R, Infante A, Focaccetti C, Lucarini V, Cifaldi L, Masuelli L, **Mutti L**, Palumbo C, Benvenuto M, Bei R. Combining Chemotherapeutic Agents, Targeted Therapies, Vaccines and Natural Bioactive Compounds for Mesothelioma: Advances and Perspectives. *Oncol Res.* 2025 Aug 28;33(9):2181-2204. doi: 10.32604/or.2025.066708. PMID: 40918456; PMCID: PMC12408854.
176. Gray SG, **Mutti L**. "WEE"ding Out Resistance to Osimertinib in the "ARID"1A-Mutated Badlands. *J Thorac Oncol.* 2025 Oct;20(10):1366-1368. doi: 10.1016/j.jtho.2025.07.120. PMID: 41047183.

Prof. Luciano Mutti

2/11/2025